Precision-Based, Risk-Stratified Management of IgA Nephropathy: Clinical Decision Algorithm
Authored by Sourabh Sharma, published on 2026-11-19 03:39:26.0
This algorithm presents a comprehensive, evidence-based approach to the diagnosis, risk stratification and management of primary IgA nephropathy (IgAN). It integrates conventional supportive care and nephroprotective strategies with emerging disease-modifying therapies, including FDA-approved targeted treatments acting on pathogenic IgA production, complement activation and downstream glomerular injury. The algorithm aims to facilitate individualised, risk-based therapeutic decisions, optimise proteinuria control, preserve kidney function and improve long-term renal outcomes.Clinical notes1. IgAN diagnosis requires kidney biopsy. Consider biopsy in adults with suspected IgAN and proteinuria ≥0.5 g/day, where appropriate.2. Risk assessment should integrate eGFR, proteinuria, eGFR trajectory, blood pressure, Oxford MEST-C classification and the International IgAN Prediction Tool. Histological scores and prediction tools should inform prognosis, not independently dictate treatment selection.3. Treatment should aim for proteinuria below 0.5 g/day, ideally below 0.3 g/day, and preservation of kidney function.4. Optimised supportive care, including maximally tolerated ACE inhibitor/ARB therapy, SGLT2 inhibitors where appropriate, dietary sodium restriction and cardiovascular risk management, remains fundamental.5. Disease-specific treatment should be individualised according to clinical risk, eligibility, mechanism of action, contraindications and patient preferences.6. Newer therapies targeting APRIL/BAFF, complement pathways and endothelin receptors should be considered according to their respective clinical evidence and regulatory indications. These include targeted-release budesonide, sparsentan, iptacopan, atrasentan, sibeprenlimab, atacicept and ravulizumab.7. Evidence supporting simultaneous combination of multiple newer disease-specific therapies remains limited. Treatment sequencing should therefore be guided by available evidence rather than presumed additive efficacy.8. Systemic glucocorticoids and other immunosuppressants should be reserved for appropriately selected clinical situations, with careful assessment of infection risk and treatment-related toxicity.9. Rapidly progressive IgAN, nephrotic syndrome, pregnancy, paediatric IgAN and post-transplant recurrence require separate clinical consideration.10. FDA approval should not be equated with CDSCO approval or availability in India. Drug access, affordability, monitoring requirements and local regulatory status must be considered.
Assess Hematuria, Proteinuria, eGFR, BP, Albumin, Sediment, and Secondary Causes
Determine Biopsy Need; Biopsy Suspected IgAN at Proteinuria ≥0.5 g/day and Report MEST-C
Primary Adult IgAN Confirmed Without a Special Presentation?
Apply Prediction Tool; Track Proteinuria, eGFR Slope, and MEST-C Prognostically
Maximize ACEi/ARB, Add SGLT2i, and Optimize Lifestyle and Cardiovascular Risk
Proteinuria <0.5 g/day, Ideally <0.3, With Near-Physiologic eGFR Slope?
Continue Nephroprotection and Monitor Proteinuria and eGFR Longitudinally
Active Modifiable Disease Versus Advanced Irreversible Chronic Damage?
Match Disease Activity, FDA Eligibility, Safety, Local Access, and Preference
Select Therapy by Activity, Eligibility, Safety, Access, RAS Strategy, and Preference; Avoid Routine Combinations
Select Pathogenic IgA-Production Therapy
Start 9-Month Targeted-Release Budesonide (TARPEYO; Traditional Approval)
Reassess Proteinuria, eGFR Slope, Safety, and Adherence Every 3–6 Months
Target Response, Partial/No Response, or Irreversible Progression?
Continue Effective Therapy; Maintain Nephroprotection and Long-Term Surveillance
Expert Review: Switch or Sequence; Avoid Unsupported Drug Combinations
Prepare Kidney Replacement Therapy and Transplant Evaluation
Start Sibeprenlimab (VOYXACT; Accelerated Approval) When Eligible
Reassess Proteinuria, eGFR Slope, Safety, and Adherence Every 3–6 Months
Target Response, Partial/No Response, or Irreversible Progression?
Continue Effective Therapy; Maintain Nephroprotection and Long-Term Surveillance
Expert Review: Switch or Sequence; Avoid Unsupported Drug Combinations
Prepare Kidney Replacement Therapy and Transplant Evaluation
Start Atacicept (TRUTAKNA; Accelerated Approval) When Eligible
Reassess Proteinuria, eGFR Slope, Safety, and Adherence Every 3–6 Months
Target Response, Partial/No Response, or Irreversible Progression?
Continue Effective Therapy; Maintain Nephroprotection and Long-Term Surveillance
Expert Review: Switch or Sequence; Avoid Unsupported Drug Combinations
Prepare Kidney Replacement Therapy and Transplant Evaluation
Select Endothelin Therapy by Background RAS Strategy
Replace ACEi/ARB With Sparsentan (FILSPARI; Traditional Approval)
Reassess Proteinuria, eGFR Slope, Safety, and Adherence Every 3–6 Months
Target Response, Partial/No Response, or Irreversible Progression?
Continue Effective Therapy; Maintain Nephroprotection and Long-Term Surveillance
Expert Review: Switch or Sequence; Avoid Unsupported Drug Combinations
Prepare Kidney Replacement Therapy and Transplant Evaluation
Add Atrasentan (VANRAFIA; Accelerated Approval) to Background RAS Blockade
Reassess Proteinuria, eGFR Slope, Safety, and Adherence Every 3–6 Months
Target Response, Partial/No Response, or Irreversible Progression?
Continue Effective Therapy; Maintain Nephroprotection and Long-Term Surveillance
Expert Review: Switch or Sequence; Avoid Unsupported Drug Combinations
Prepare Kidney Replacement Therapy and Transplant Evaluation
Select Alternative or Terminal Complement Inhibition After Infection Review
Vaccinate Per Label; Start Iptacopan (FABHALTA; Traditional Approval)
Reassess Proteinuria, eGFR Slope, Safety, and Adherence Every 3–6 Months
Target Response, Partial/No Response, or Irreversible Progression?
Continue Effective Therapy; Maintain Nephroprotection and Long-Term Surveillance
Expert Review: Switch or Sequence; Avoid Unsupported Drug Combinations
Prepare Kidney Replacement Therapy and Transplant Evaluation
Vaccinate Per Label; Start IV Ravulizumab (ULTOMIRIS; Accelerated Approval)
Reassess Proteinuria, eGFR Slope, Safety, and Adherence Every 3–6 Months
Target Response, Partial/No Response, or Irreversible Progression?
Continue Effective Therapy; Maintain Nephroprotection and Long-Term Surveillance
Expert Review: Switch or Sequence; Avoid Unsupported Drug Combinations
Prepare Kidney Replacement Therapy and Transplant Evaluation
Use Reduced-Dose Steroids; Reserve MMF for Selected Chinese Patients
Reassess Proteinuria, eGFR Slope, Safety, and Adherence Every 3–6 Months
Target Response, Partial/No Response, or Irreversible Progression?
Continue Effective Therapy; Maintain Nephroprotection and Long-Term Surveillance
Expert Review: Switch or Sequence; Avoid Unsupported Drug Combinations
Prepare Kidney Replacement Therapy and Transplant Evaluation
Prepare Kidney Replacement Therapy and Transplant Evaluation
Prepare Kidney Replacement Therapy and Transplant Evaluation
Use Dedicated Secondary, RPGN, Nephrotic/MCD, Pregnancy, Pediatric, or Transplant Pathway
Evaluate Alternative Causes; Individualize Biopsy or Nephrology Surveillance
Continue Nephroprotection and Monitor Proteinuria and eGFR Longitudinally